Mounjaro Dosing Schedule: Step-by-Step Guide

Last reviewed: July 13, 2026

Last updated: July 13, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that requires a stepwise dosing approach to achieve optimal weight loss and metabolic outcomes. Unlike fixed-dose regimens, tirzepatide treatment with PlexusDx follows an evidence-based titration protocol where your dose increases every four weeks based on tolerability and clinical response. Understanding this progression helps you know what to expect as you begin your personalized weight loss journey.

What Is the Standard Tirzepatide Starting Dose?

Tirzepatide treatment begins at 2.5 milligrams injected once weekly, a starter dose designed to allow your body to adapt to the medication while you monitor for side effects. This initial four-week phase establishes your baseline tolerance before advancing to the next step. Most patients experience minimal gastrointestinal effects at this entry dose, making the first month a reliable introduction to how tirzepatide affects your appetite and metabolism.

The 2.5 mg starting point is based on clinical trial data showing that gradual titration improves adherence and reduces withdrawal from treatment due to side effects. PlexusDx delivers this initial dose as a subcutaneous injection you administer at home once per week, on the same day each week for consistency. Your healthcare provider will review your response after four weeks before determining if advancement to the next tier is appropriate.

Understanding the Four-Week Titration Steps

After your first month on 2.5 mg, tirzepatide treatment progresses to 5 mg weekly during weeks five through eight, provided you tolerate the starter dose well. This second step doubles your initial dose and typically begins to show measurable effects on appetite suppression and weight loss. The four-week intervals between increases allow sufficient time to assess how each dose level affects your hunger hormones, blood sugar regulation, and body composition.

Weeks nine through twelve move you to the 7.5 mg weekly dose, which represents the mid-range step in the standard progression. By this point, many patients report noticeable shifts in food preferences and portion control without actively restricting calories. The 7.5 mg dose marks a transition where the dual GIP/GLP-1 mechanism becomes increasingly active in reducing appetite signaling through your brain's satiety centers.

Maintenance Dosing and Individual Optimization

The maintenance phase typically involves 10 mg to 15 mg of tirzepatide injected weekly, though some patients achieve their weight loss and metabolic goals at lower maintenance levels. Clinical trial data shows that 15 mg weekly represents the maximum recommended dose in most protocols, with robust results observed across the 10–15 mg range. PlexusDx works with you to identify your optimal maintenance dose—the dose at which you experience meaningful appetite reduction and weight loss with tolerable side effects, ensuring consistent monthly pricing regardless of which maintenance tier you reach.

Not every patient requires escalation to the highest dose to see results. Your genetic makeup, metabolic factors, and clinical response guide whether you maintain at 10 mg, 12.5 mg, or 15 mg weekly. The Precision Peptide Genetic Test offered by PlexusDx screens key variants in the GLP1R and GIPR genes that influence how efficiently your body responds to tirzepatide, helping optimize your personalized dosing path from the start.

Managing Side Effects During Tirzepatide Titration

Mild to moderate nausea, constipation, and reduced appetite are common during the first two to four weeks of tirzepatide treatment, as your gastrointestinal system adjusts to increased satiety signaling. Most patients find these effects diminish substantially by week four, especially if they stay well-hydrated, eat smaller meals, and avoid high-fat foods. If side effects become intolerable, your PlexusDx provider can extend your titration timeline, holding your current dose for an additional two to four weeks before advancing.

Severe or persistent side effects should prompt immediate contact with your healthcare team, though they are rare when titration is followed correctly. Adjusting your injection timing, meal composition, and hydration often resolves minor discomfort without halting treatment. PlexusDx provides ongoing clinical support during your titration period to ensure you stay on track and address concerns as they arise, helping you complete your dosing schedule successfully.

Why Gradual Tirzepatide Dosing Improves Outcomes

Research demonstrates that stepped titration protocols produce better long-term adherence and sustained weight loss compared to fixed or accelerated dosing approaches. The four-week intervals allow your body's GLP-1 and GIP receptors to upregulate efficiently, maximizing the medication's effects on insulin secretion, glucagon suppression, and appetite regulation. This biological adaptation period is critical for achieving durable metabolic change rather than rapid but temporary weight reduction.

Gradual progression also reduces the risk of severe gastrointestinal adverse events that can lead patients to discontinue treatment prematurely. By the time you reach maintenance dose, your tolerance is established and side effects typically plateau at mild or manageable levels. PlexusDx's flat pricing model supports this evidence-based titration approach—your monthly cost remains consistent as your dose increases, removing financial barriers to completing your full treatment protocol.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

How long does the entire tirzepatide dosing schedule take?

The standard titration from 2.5 mg to maintenance dose takes approximately 12 weeks (three months), with four-week intervals between increases. Some patients may extend this timeline if they need additional time to tolerate each step. PlexusDx providers can customize your titration pace based on your individual tolerance and clinical goals.

Can I skip doses or go faster through tirzepatide titration?

Accelerating tirzepatide titration increases the risk of severe nausea, vomiting, and dehydration, potentially leading to treatment discontinuation. Clinical trials used the four-week protocol to maximize tolerability and treatment completion. Your PlexusDx provider will work with you if you need adjustments, but evidence strongly supports following the standard schedule.

What is the cost of tirzepatide at each dosing level with PlexusDx?

PlexusDx offers compounded tirzepatide injections at $289/mo month-to-month, or from $249/mo on the 6-month plan with flat pricing across all dose levels—your monthly cost remains the same whether you are on 2.5 mg or 15 mg weekly. No membership fees or insurance required, and the medication is HSA/FSA eligible for added savings.

What happens if I experience severe side effects during tirzepatide dosing?

Contact your PlexusDx provider immediately if you have persistent vomiting, severe dehydration, or signs of pancreatitis. Your provider can pause titration, extend intervals between doses, or adjust your maintenance target. Severe adverse events are rare with proper titration, but your clinical safety is the top priority.

How does the Precision Peptide Genetic Test relate to your GLP-1 pathway?

Yes—PlexusDx's Precision Peptide Genetic Test identifies variants in GLP1R (rs6923761) and GIPR (rs1800437) that influence tirzepatide response. Patients with certain genetic profiles may reach their goals at lower maintenance doses, while others benefit from higher levels. This $99 add-on test (after your first month) personalizes your titration path and supports optimal dosing decisions.

Related Reading

• Tirzepatide Dosing Schedule Plexusdx
• Hers Mounjaro
• Hims Mounjaro
• Mounjaro For Hypertension

Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.